Corcept Therapeutics Incorporated (CORT) Q4 2013 Earnings Results

Corcept Therapeutics Beats on EPS, Stock Up 2.56%

Corcept Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 2.56%. The lack of revenue figures and guidance may leave investors cautious, but the EPS beat suggests better-than-anticipated cost management. Moving forward, the company appears focused on operational improvements and future growth strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.09	N/A	+19.64%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their focus on cost management and future growth opportunities.

Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.

They highlighted ongoing efforts to improve operational efficiency.

Corcept Therapeutics Beats on EPS, Stock Up 2.56%

Key numbers

Management commentary

Corcept Therapeutics Incorporated

More earnings this week

Corcept Therapeutics Beats on EPS, Stock Up 2.56%

Key numbers

Management commentary